Professor Patricia McGettigan
Professor of Clinical Pharmacology and Medical Education (HCC)
Centre: Clinical Pharmacology and Precision Medicine
Email: p.mcgettigan@qmul.ac.ukTelephone: +44(0) 20 7882 7128
Profile
ORCID iD: 0000-0002-9757-9754
Patricia McGettigan is a Clinical Pharmacologist and Consultant Physician at Queen Mary University of London (QMUL) and Barts Health NHS Trust. She graduated in pharmacy and in medicine from the University of Dublin, Trinity College and trained in Clinical Pharmacology at Trinity College, Dublin and the University of Newcastle, New South Wales, Australia. She is head of MBBS clinical pharmacology, therapeutics and prescribing teaching at QMUL and co-leads final year Clinical Trials and Regulatory Affairs teaching in QMUL’s BSc in Pharmacology and Innovative Therapeutics.
She is Deputy Chair of the Medical Schools Council’s national Prescribing Safety Assessment Standard Setting Group and an External Examiner for pharmacology at University College Cork, Ireland. In her clinical role, based at Barts Health Royal London Hospital, she cares for cardiology in-patients and provides specialist HIV-cardiovascular risk management for out-patients.
She is a Fellow of the Royal College of Physicians in Ireland, the Royal Australasian College of Physicians and the British Pharmacological Society and a Senior Fellow of the Higher Education Academy. Active in both national and European medicines regulation, she is a Member of the UK’s Commission on Human Medicines Pharmacovigilance Expert Advisory Group and is appointed by the European Commission to the Pharmacovigilance and Risk Management Committee of the European Medicines Agency.
Research
Patricia McGettigan’s research focuses on pharmacoepidemiology and medicines regulation using large health registers, drug sales databases, and regulatory records. In pharmacoepidemiology, major interests relate to drug-associated adverse events, medicines utilisation, and HIV-co-morbidities. Her regulatory research is on the authorisation of medicines, including fixed dose combination products and regulatory system failures in India, and the role of patient/disease registries in supporting post-authorisation medicines evaluation.
Publications
-
Malik ME, Koeber L, Garred CH et al. (2024). Hyponatremia and risk of new-onset heart failure in patients with type 2 diabetes - a real-world study of 70,000 patients. nameOfConference
-
Nielsen S, Holt AH, Lamberts ML et al. (2024). Pregnancy protection in women of child-bearing age prescribed ACE inhibitors, ARBs or statins - A nationwide cohort study. nameOfConference
-
de Abreu Nunes L, Hooper R, McGettigan P et al. (publicationYear). Statistical methods leveraging the hierarchical structure of adverse events for signal detection in clinical trials: a scoping review of the methodological literature. nameOfConference
-
Bogowicz P, Mehta A, Choudhary S et al. (2024). Sales and regulatory status of fixed dose combination psychotropic drugs in India: a retrospective longitudinal study. nameOfConference
-
Holt A, McGettigan P, Lamberts M (2024). Unmeasured confounding is always unnerving: cannabis and cardiovascular risk. nameOfConference
-
Nielsen SK, Lamberts M, Nouhravesh N et al. (2024). Temporal trend of first-line drug choice and treatment continuity for hypertension among citizens 75 years or over - a register-based, cohort study. nameOfConference
-
Holt A, Strange JE, Rasmussen PV et al. (2024). Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults. nameOfConference
-
Brhlikova P, Mehta A, McGettigan P et al. (2023). Regulatory enforcement of the marketing of fixed-dose combinations in India: a case study of systemic antibiotics. nameOfConference
QMRO: qmroHref -
Holt A, Nouhravesh N, Strange JE et al. (2024). Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study. nameOfConference
-
Holt A, Strange JE, Rasmussen PV et al. (2023). Long-term risk of cardiovascular side-effects following attention-deficit hyperactivity disorder treatment with sympathomimetic amines. nameOfConference
QMRO: qmroHref
Collaborators
University of Copenhagen, Denmark: Dr Anne-Marie Schjerning-Olsen, Dr Morten Lamberts, Professor Gunnar Gislason; University of Newcastle, UK: Dr Petra Sevcikova, Mr Peter Roderick, Professor Allyson Pollock; Indian Council of Medical Research: Professor Nilima Krishsagar; Public Health Foundation of India: Dr Habib Hasan Farooqui; University of Dundee, Scotland: Dr Daniel Morales.
News
- Many fixed-dose drug combinations in India lack central regulatory approval, (Queen Mary University of London / PLOS Medicine), May 2015